**Supplementary Table 6. Incidence of adverse events by study stage**

|  | **Arm** |
| --- | --- |
| **Linaclotide** | **Placebo** | **Total** |
| **N** | **%** | **N** | **%** | **N** | **%** |
| **Stage** | **System of Complaint** | **CTCAE Term** |  |  |  |  |  |  |
| **All Stages** | **Gastrointestinal**  | **Abdominal distension** | 1 | 8.3% |  |  | 1 | 4.2% |
| **Abdominal pain** | 2 | 16.7% | 1 | 8.3% | 3 | 12.5% |
| **Bloating** | 1 | 8.3% | 3 | 25.0% | 4 | 16.7% |
| **Constipation** |  |  | 1 | 8.3% | 1 | 4.2% |
| **Diarrhea** | 7 | 58.3% | 7 | 58.3% | 14 | 58.3% |
| **Flatulence** |  |  | 4 | 33.3% | 4 | 16.7% |
| **Other**  | 5 | 41.7% | 2 | 16.7% | 7 | 29.2% |
| **Nausea** | 1 | 8.3% |  |  | 1 | 4.2% |
| **Stomach pain** |  |  | 1 | 8.3% | 1 | 4.2% |
| **Vomiting** | 1 | 8.3% | 1 | 8.3% | 2 | 8.3% |
| **General**  | **Fatigue** | 1 | 8.3% | 1 | 8.3% | 2 | 8.3% |
| **Infections and infestations** | **Infective Rhinitis**  |  |  | 1 | 8.3% | 1 | 4.2% |
| **Nervous system**  | **Headache** | 1 | 8.3% | 2 | 16.7% | 3 | 12.5% |
| **Respiratory, thoracic, mediastinal**  | **Cough** | 2 | 16.7% |  |  | 2 | 8.3% |
| **Sore throat** | 1 | 8.3% |  |  | 1 | 4.2% |
| **Skin and subcutaneous tissue**  | **Pain of skin** | 1 | 8.3% | 1 | 8.3% | 2 | 8.3% |
| **Pruritus** |  |  | 1 | 8.3% | 1 | 4.2% |
| **Other**  |  |  | 2 | 16.7% | 2 | 8.3% |

All adverse events were grade 1